端点技术解决方案提供商Clario达成最终协议收购WCG的eCOA业务-动脉网

Clario Enters into Definitive Agreement to Acquire WCG's eCOA Business

CISION 等信源发布 2025-03-11 02:36



可切换为仅中文







WCG logo

WCG标志

Clario

克拉里奥

Acquisition of WCG's electronic clinical outcome assessments (eCOA) business will expand Clario's scientific expertise and offerings in neuroscience

收购WCG的电子临床结果评估（eCOA）业务将扩展Clario在神经科学领域的科学专业知识和服务。

PHILADELPHIA

费城

，

March 10, 2025

2025年3月10日

/PRNewswire/ --

Clario

克拉里奥

, a leading provider of endpoint data solutions to the clinical trial industry, today announced they have entered into a definitive agreement to acquire the eCOA business of WCG, a leader in providing solutions that measurably improve and accelerate clinical research.

，临床试验行业的端点数据解决方案的领先提供商，今天宣布他们已经达成了一项最终协议，收购WCG的eCOA业务，WCG是提供可显著改进和加速临床研究解决方案的领导者。

Electronic clinical outcomes assessments (eCOA), in addition to paper assessments, are used to evaluate the safety and efficacy of new drugs by measuring how a clinical trial participant feels or functions. WCG's eCOA operations offer robust, full-service clinical expertise and specialized functionality, particularly in neurology, psychiatry, neuropathic pain, and rare diseases.

电子临床结果评估 (eCOA) 除了纸质评估外，还通过测量临床试验参与者的感觉或功能来评估新药的安全性和有效性。WCG的eCOA运营提供强大、全面的临床专业知识和专业功能，尤其是在神经病学、精神病学、神经性疼痛和罕见疾病领域。

。

'WCG's eCOA business has a well-earned reputation for industry-leading expertise in neuroscience. Adding their scientific and operational capabilities to expand our neuroscience capabilities in imaging and digital physiology aligns with Clario's vision to transform lives by unlocking actionable evidence,' said Chris Fikry, M.D., chief executive officer, Clario.

“WCG的eCOA业务在神经科学领域拥有当之无愧的行业领先专业知识声誉。将他们的科学和运营能力加入到我们的团队，以扩展我们在成像和数字生理学方面的神经科学能力，这与Clario通过解锁可行证据来改变生活的愿景是一致的，”Clario首席执行官Chris Fikry博士说道。

'I am excited about the long-term positive impact this will have on customers and patients.'.

“我对这将给客户和患者带来的长期积极影响感到兴奋。”

'WCG's eCOA expertise and capabilities in subjective endpoints are a strategic and complementary fit with Clario's endpoint solutions. This transaction allows WCG to focus on being a trusted partner in connecting sponsors and CROs with sites to accelerate trials through trial design, study review, site activation, and participant recruitment and retention,' said .

“WCG在主观终点指标方面的电子临床结局评估（eCOA）专业知识和能力，与Clario的终点解决方案形成了战略性和互补性的契合。此次交易使WCG能够专注于成为连接申办方和合同研究组织（CRO）与试验站点的可信赖合作伙伴，通过试验设计、研究审查、站点启动以及参与者招募和保留来加速临床试验。”

Sam Srivastava

萨姆·斯里瓦斯塔瓦

, chief executive officer, WCG. 'With a legacy of supporting clinical trials over more than five decades across 130 countries, we remain well-positioned to accelerate clinical research through our AI-enabled data, technology, and expertise, paving the way to bring life-saving therapies to patients, faster.'.

“WCG首席执行官表示：‘凭借在130个国家超过五十年支持临床试验的经验，我们通过人工智能赋能的数据、技术和专业知识，加速临床研究，为患者更快带来挽救生命的疗法。’”

Customers of both companies can expect no immediate changes to existing contracts or relationships.

两家公司的客户可以预计现有合同或关系不会立即发生变化。

'This complementary acquisition will augment our offerings by expanding our scientific expertise and service delivery capabilities,' said Clario EVP and General Manager of eCOA,

“这项互补性收购将通过扩展我们的科学专业知识和服务交付能力来增强我们的产品 offerings，”Clario 执行副总裁兼 eCOA 总经理表示。

Terry Burke

特里·伯克

. 'I am delighted that we will be positioned to further enable the success of our customers and ultimately have a greater impact on patients with unmet medical needs.'

“我感到非常高兴，我们将能够进一步助力客户的成功，并最终对那些未被满足医疗需求的患者产生更大的影响。”

The transaction is subject to regulatory approvals and other customary closing conditions. Until the acquisition closes, both organizations will continue to operate as independent entities.

该交易需经监管机构批准和其他惯例的交割条件。在收购完成之前，两家组织将继续作为独立实体运营。

About Clario

关于Clario

Clario is a leading provider of endpoint data solutions to the clinical trials industry, generating high-quality clinical evidence for life sciences companies. We offer comprehensive evidence-generation solutions that combine medical imaging, eCOA, precision motion, cardiac solutions and respiratory endpoints..

Clario是为临床试验行业提供终点数据解决方案的领先提供商，为生命科学公司生成高质量的临床证据。我们提供全面的证据生成解决方案，结合了医学影像、电子临床结果评估（eCOA）、精密运动、心脏解决方案和呼吸终点。

For more than 50 years, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have been deployed over 26,000 times to support clinical trials in more than 100 countries. Our global team of science, technology, and operational experts have supported over 60% of all FDA drug approvals since 2012.

五十多年来，Clario 一直提供深厚的科学专业知识和广泛的终点技术，助力改变全球人们的生活。我们的终点数据解决方案已被部署超过 26,000 次，支持了 100 多个国家的临床试验。自 2012 年以来，我们由科学、技术和运营专家组成的全球团队已参与支持了超过 60% 的 FDA 药品批准。

Clario's shareholders are Astorg, Nordic Capital, Novo Holdings, and Cinven..

Clario的股东是Astorg、Nordic Capital、Novo Holdings和Cinven。

For more information, go to

更多信息，请访问

Clario.com

克莱里奥网

or follow us on

或者关注我们

领英

。

About WCG

关于WCG

WCG is a global leader of solutions that measurably improve and accelerate clinical research. Biopharmaceutical and medical device companies, contract research organizations (CROs), research institutions, and sites partner with us for our unmatched expertise, data intelligence, and purpose-built technology to make informed decisions and optimize study outcomes, while maintaining the highest standards of human participant protection.

WCG是全球领先的解决方案提供商，可显著改进和加速临床研究。生物制药和医疗器械公司、合同研究组织 (CRO)、研究机构和站点与我们合作，借助我们无与伦比的专业知识、数据智能和专为目标打造的技术，做出明智决策并优化研究结果，同时坚持人类参与者保护的最高标准。

WCG raises the bar by pioneering new concepts, reimagining processes, fostering compliance and safety, and empowering those who perform clinical trials to accelerate the delivery of medical therapies and devices that improve lives. For more information, please visit .

WCG通过开创全新理念、重新构想流程、促进合规与安全，以及赋能临床试验执行者加速交付改善生命的医疗疗法和设备，树立了更高的标准。欲了解更多信息，请访问。

wcgclinical.com

or follow us on

或关注我们

领英

or X

或 X

@WCGClinical

@WCG临床

。

Clario Media Contact:

克拉里奥媒体联系人：